GSK PLC Sponsored ADR (NYSE:GSK) Declares $0.42 Quarterly Dividend

Key Points

• GSK PLC has declared a quarterly dividend of $0.42 per share, to be paid on October 9th to shareholders recorded by August 15th, resulting in an annualized yield of 4.5%.
• The company reported $1.23 earnings per share for the last quarter, surpassing analyst expectations of $1.12, and noted quarterly revenue of $10.64 billion.
• Following these announcements, GSK's stock traded down 4.7% to $37.15, with a market capitalization of $75.83 billion.

GSK PLC Sponsored ADR (NYSE:GSK - Get Free Report) declared a quarterly dividend on Thursday, July 31st, Wall Street Journal reports. Shareholders of record on Friday, August 15th will be given a dividend of 0.4206 per share by the pharmaceutical company on Thursday, October 9th. This represents a c) dividend on an annualized basis and a yield of 4.5%. The ex-dividend date is Friday, August 15th.

GSK has a dividend payout ratio of 35.5% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect GSK to earn $4.65 per share next year, which means the company should continue to be able to cover its $1.72 annual dividend with an expected future payout ratio of 37.0%.

GSK Trading Down 4.7%

NYSE GSK traded down $1.83 during trading hours on Thursday, reaching $37.15. The company had a trading volume of 8,004,697 shares, compared to its average volume of 5,379,957. The stock has a 50-day moving average of $39.02 and a 200 day moving average of $37.60. GSK has a 1-year low of $31.72 and a 1-year high of $44.67. The company has a current ratio of 0.87, a quick ratio of 0.58 and a debt-to-equity ratio of 1.21. The stock has a market capitalization of $75.83 billion, a P/E ratio of 19.15, a price-to-earnings-growth ratio of 1.53 and a beta of 0.50.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.12 by $0.11. GSK had a net margin of 9.89% and a return on equity of 48.82%. The company had revenue of $10.64 billion for the quarter, compared to analyst estimates of $7.92 billion. During the same period in the prior year, the firm earned $0.43 earnings per share. The business's revenue for the quarter was up 1.3% compared to the same quarter last year. As a group, research analysts anticipate that GSK will post 4.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GSK

Several large investors have recently modified their holdings of GSK. Kingsview Wealth Management LLC lifted its holdings in shares of GSK by 1.8% during the first quarter. Kingsview Wealth Management LLC now owns 15,227 shares of the pharmaceutical company's stock worth $590,000 after purchasing an additional 271 shares during the period. Rehmann Capital Advisory Group lifted its holdings in GSK by 4.6% in the first quarter. Rehmann Capital Advisory Group now owns 6,407 shares of the pharmaceutical company's stock valued at $248,000 after acquiring an additional 279 shares during the period. First PREMIER Bank lifted its holdings in GSK by 6.5% in the first quarter. First PREMIER Bank now owns 4,659 shares of the pharmaceutical company's stock valued at $181,000 after acquiring an additional 286 shares during the period. Northwest Bank & Trust Co lifted its holdings in GSK by 1.3% in the fourth quarter. Northwest Bank & Trust Co now owns 22,405 shares of the pharmaceutical company's stock valued at $765,000 after acquiring an additional 289 shares during the period. Finally, OneAscent Financial Services LLC lifted its holdings in GSK by 3.9% in the first quarter. OneAscent Financial Services LLC now owns 7,700 shares of the pharmaceutical company's stock valued at $297,000 after acquiring an additional 292 shares during the period. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.